THE WHAT? Coty has reported better-than-expected Q1 revenue, bolstered by faster growth in its mass-market division, which grew 12 percent YOY.
THE DETAILS The increase beat the prestige arm, which rose 7 percent, with the mass-market win highlighting a change from the prior quarter, where the luxury arm reported a higher increase.
Q1 revenue reached US$1.39 billion, higher than the US$1.38 billion predicted by Bloomberg analysts.
According to Coty, “Revenue growth in cosmetics and mass fragrances was broadly in-line to ahead of sell-out, the division was boosted by a strong launch pipeline and brand initiatives in its bodycare business, including adidas’ Skin & Mind premium and sustainable bodycare range, Monange’s silicone-free deodorant, and Bozzano’s clinical range.”
Geographically, EMEA like-for-like sales grew 11 percent, boosted by ‘significant travel retail momentum and double digital growth across most markets”, while Americas saw strong momentum in Brazil and Latin America.
The ‘continued strength’ in the U.S. was counter-balanced by supply constraints. Asia Pacific grew 12 percent YOY.
THE WHY? Sue Y. Nabi, Coty’s CEO, said: “Our strong Q1 results, in the midst of a complex external environment including ongoing component shortages, confirm the strength and resilience of Coty’s brands, teams, strategy and operating model. This represents the ninth consecutive quarter of Coty reporting results in-line to ahead of expectations. The progress we continue to make should be evident across all key financial KPIs, from sales to gross margins and adjusted EBITDA to our deleveraging progress.
“While Coty has certainly benefited from a resilient beauty category, I am particularly pleased that our balanced growth strategy remains in full force. We delivered robust growth across all of our regions, each of our key categories including fragrances, cosmetics, skincare and bodycare, and across both divisions. This has allowed us to again report sales growth well above the underlying beauty market and among the best in our competitive set.”
Injectable aesthetics are popular due to their ability to provide noticeable results with minimal downtime compared to surgical procedures. They are versatile and can be tailored to meet individual aesthetic goals, whether it's enhancing lips, restoring facial volume, or smoothing out wrinkles. However, they should always be administered by qualified professionals to ensure safety and achieve optimal results.
Injectable aesthetics are used to enhance facial features, reduce the signs of aging, and improve overall facial symmetry and appearance.
Key types of injectable aesthetics include:
-
Dermal Fillers: These injectables are used to add volume, fill in wrinkles and folds, and enhance facial contours. They often contain substances like hyaluronic acid, collagen, or calcium hydroxylapatite, which help plump up the skin and smooth out fine lines and wrinkles.
-
Botulinum Toxin (Botox): Botulinum toxin injections temporarily relax facial muscles that cause wrinkles and lines to form. It is commonly used to treat forehead lines, frown lines between the eyebrows, and crow's feet around the eyes.
-
Collagen Stimulators: These injectables stimulate the body's own collagen production, helping to improve skin texture and firmness over time. Examples include poly-L-lactic acid (Sculptra) and calcium hydroxylapatite (Radiesse).
-
Neurotoxin Injections: Besides Botox, other neurotoxins such as Dysport and Xeomin are used similarly to reduce wrinkles and lines.
